Amitriptylin ( DrugBank: Amitriptylin )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
299嚢胞性線維症4

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01309178
(ClinicalTrials.gov)
May 20094/3/2011Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and PlaceboAnti-inflammatory Pulmonal Therapy of CF Patients With Amitriptyline and Placebo - a Randomised, Double-blind, Placebo-controlled, Multicenter, Cohort - StudyCystic Fibrosis;PneumoniaDrug: Amitriptyline;Drug: ManniteUniversity Children’s Hospital TuebingenUniversität Duisburg-Essen;University of UlmRecruiting14 Years65 YearsBoth30Phase 2Germany
2EUCTR2006-002259-33-DE
(EUCTR)
10/10/200611/07/2006Protocol for a Phase II-studyAnti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo - a randomised, double-blinded, placebo-controlled, cross over study -Protocol for a Phase II-studyAnti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo - a randomised, double-blinded, placebo-controlled, cross over study - CF-patients develop a chronic pulmonary infection with Pseudomonas aeruginosa (P. aeruginosa). At present it is unknown why CF-patients are highly sensitive to P. aeruginosa infections and, most important, no curative treatment for cystic fibrosis is available. This Study should provide a novel anti-inflammatory treatment for cystic fibrosis, which reduces pulmonary complications, progression of the disease and may possibly increase the life-expectance of the patients.Trade Name: Amitriptylin-ct Tabletten
Product Name: Amitriptyline
INN or Proposed INN: AMITRIPTYLINE
Trade Name: Amitriptylin-ct Tabletten
Product Name: Amitriptyline
INN or Proposed INN: AMITRIPTYLINE
Trade Name: Amitriptylin-ct Tabletten
Product Name: Amitriptyline
INN or Proposed INN: AMITRIPTYLINE
Paediatrisches Sekretariat fuer Klinische StudienNULLNot RecruitingFemale: yes
Male: yes
18Phase 2Germany
3NCT00515229
(ClinicalTrials.gov)
October 20069/8/2007Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and PlaceboProtocol for a Phase II-Study Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo - Randomised, Double-Blinded, Placebo-Controlled, Cross Over - Study -Cystic Fibrosis;Infection;Pseudomonas AeruginosaDrug: amitriptylineUniversity Hospital TuebingenNULLCompleted18 Years50 YearsBoth18Phase 2Germany
4EUCTR2008-002673-13-DE
(EUCTR)
27/08/2008Anti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and PlaceboAnti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo Deficiency of the Cftr-molecule results in accumulation of ceramide in respiratory epithelial cells. Ceramide triggers a pro-inflammatory and -apoptotic status in cystic fibrosis patients. Amitriptyline reduces ceramide levels in the lung tissue, normalises the activity of cytokines and prevents constitutive cell death of epithelial cells. Amitriptyline prevents pulmonary infections of CF-mice with P. aeruginosa. Amitriptyline may result in an improved lung function of cystic fibrosis patients.Trade Name: Amitriptylin-CT
Product Name: Amitriptyline
INN or Proposed INN: Amitriptyline
PSKSNULLNot RecruitingFemale: yes
Male: yes
Phase 2Germany